| INTRODUCTION

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI)
disorder of unknown etiology. Low grade activation of the GI mucosal immune system has been proposed as one of the underlying mechanisms of IBS. 1, 2 Studies have shed light into the potential role of immune activation on bowel physiology, including the impact of immune and enteroendocrine factors released by the intestinal mucosa on epithelial permeability, 3 enteric nervous system function, 4 and sensory nerve activation. [5] [6] [7] In the healthy GI tract, the immune system maintains a physiological balance when facing environmental stimuli including allergens, dietary antigens, commensal microorganisms, or pathogens. The differences in luminal contents, anatomy, and function along the length of the gut are associated with variability in the immune cell types and immunological responses in each segment of the gut. In the colon which is the main reservoir for commensal microbiota, immune response to these microorganisms is suppressed. 
| METHODS
| Search strategy and study selection
In February 2017, two independent reviewers (S. Moossavi and S.
Moraveji) conducted a search in PubMed and Embase using the following terms: (i) "irritable bowel syndrome", (ii) immun*, (iii) inflamm*, (iv) lymphocyte, (v) leukocyte, (vi) "mast cell", (vii) macrophage, (viii) basophil, (ix) "dendritic cell", (x) "natural killer cell", (xi) eosinophil, (xii) "B cell", (xiii) B-cell, (xiv) "T cell", (xv) T-cell, (xvi) "T-Helper", (xvii) "T Helper", (xviii) "T-Cytotoxic", (xix) "T Cytotoxic", (xx) ii or iii or iv or v or vi or vii or viii or ix or x or xi or xii or xiii or xiv or xv or xvi or xvii or xviii or xix, and (xxi) i and xxi. The titles and abstracts of the retrieved articles were screened for duplicates and relevance to the topic. Subsequently, full texts of the articles on immune cells in IBS were retrieved and further evaluated to identify case-control studies on colonic immune cells in IBS patients vs healthy controls.
Similar to our previous meta-analysis on IBS, 9 case-control studies 
Key Points
• Studies have indicated changes in the intestinal immune cell counts of IBS patients; however, these findings are not consistent.
• The current study shows that the number of colonic mast cells, CD3 + T cells and CD4 + T cells are increased in IBS.
• These changes are colonic segmental and sometimes IBSsubtype dependent.
were included if: (i) the diagnosis of IBS was established by physicians, and/or was based on the ROME I, II or III criteria, (ii) other GI diseases were excluded from both case and control groups, (iii) sample size in each group and mean ± SD and/or SEM of immune cell counts in the biopsy samples were reported and (iv) if the immunecell count in a specific intestinal region was available in ≥2 studies.
As not all studies had reported the data in the form of mean (SD) and also based on IBS-subtypes or sex, the authors' were contacted and invited to recalculate and provide the appropriate data. Our metaanalysis did not include studies on pediatric patients. Our literature review retrieved 11 studies on immune cells and small intestine.
However, the meta-analysis of small intestinal data was not comprehensively performed due to the lack of access to raw data. The flow diagram of the study selection for this meta-analysis is depicted in Figure 1 .
| Quality assessment
Quality assessment of the studies was performed by S. Moossavi and M. Bashashati, based on the modified Newcastle-Ottawa Scale (NOS) to accommodate the methodology of immune cell counts as a criterion. As previously described, 9 three separate scores were assigned for the selection, comparability and exposure (ie, laboratory methods) domains, where the sum of these three scores was equal to the total modified NOS (Table S1 ). The lowest and highest scores based on the modified NOS were 0 and 9 respectively. The total modified NOS score ≥6 indicated a good research quality of the included studies.
| Data extraction
The mean ± SD of immune cell counts in the colonic biopsies of IBS patients and healthy controls were extracted from the full-text of the included studies. In case the full-texts did not report these values, the authors of the original studies were contacted and provided the numbers which were necessary for the meta-analysis. If data was reported as median (interquartile range) or median (range), the mean and standard deviation were calculated as described previously. 25 
| Statistical analysis
Standardized mean difference (SMD), generated by the inverse variance method in Review Manager version 5.3 (The Nordic Cochrane
Centre, Copenhagen, Denmark; The Cochrane Collaboration, 2014) was chosen for this meta-analysis, as previously described.
9
Heterogeneity was assessed based on I 2 values, where I 2 > 50% indicated heterogeneity and the random-effects model was used. When I 2 was equal or less than 50%, the fixed-effects model was used.
Whenever data were available, meta-analysis based on the subtypes showed how much it contributed to the pooled estimated SMD.
| RESULTS
| Subjects and quality of the studies
Twenty-two studies which analyzed colonic mast cell and/or lymphocyte counts were included in this meta-analysis. 5, 6, [10] [11] [12] [13] [14] [15] [17] [18] [19] [20] [21] [22] [23] [24] [26] [27] [28] [29] [30] [31] The studies included a total of 706 patients with IBS and 401 controls.
The quality of the studies based on modified NOS ranged between 5 and 9 ( Table 1) .
| Colonic mast cells
The biopsies were collected from different segments of the colon;
therefore, we conducted a separate meta-analysis for each region of the other studies which were conducted by other groups also showed a significantly higher mast cell counts in the descending colon of IBS patients compared to controls. 17, 19, 20 After excluding the studies from the University of Bologna, 5,12-15 the significant difference in the mast cell count of the descending colon between IBS and controls was lost. On the other hand, after excluding these studies and the only study which showed significant decrease in mast cell counts in the descending colon in IBS vs controls, 26 the significantly higher mast cell count in the descending colon of IBS patients compared to controls remained.
In the ascending colon, there was no significant difference between IBS and control groups (Figure 2 ).
The effect of IBS subtype, sex, and history of post-infectious (PI)-IBS on colonic mast cell counts were evaluated. In IBS-C compared to healthy controls, the meta-analysis detected a significantly higher density/number of mast cells only in the descending colon, while in the IBS-D there was an increase both in the descending and rectosigmoid colon ( Figure 3 ). As for differences among the sexes, only Braak et al. 26 showed a significantly lower mast cell count in the descending colon of both men and women IBS patients compared to their respective 
| Colonic lymphocytes
Next, we investigated the presence of T cells identified as CD3 
F I G U R E 3 Density/number of mast cells in colorectal biopsies of IBS vs controls according to the IBS subtypes. (A) IBS-C in descending colon, (B) IBS-C in rectosigmoid, (C) IBS-D in descending colon, (D) IBS-D in rectosigmoid
In addition, CD4 + T cells were significantly more numerous in the rectosigmoid colon of IBS patients ( Figure 6 ). Finally, the number/frequency of CD8 + T cell was not different in biopsies of IBS patients vs controls ( Figure 7) . The number of studies on CD4 + T cells and CD8 + T cells in the descending colon was not sufficient for meta-analysis.
Based on IBS subtypes and sex, CD8 + T cell numbers, did not show any difference between the IBS and controls (data not shown).
| Small intestinal immune cells
Conducting meta-analysis on the immune cells in the small intestine of IBS patients compared to controls was not the aim of the current study due to the lack of access to the raw numbers in many of the original publications. However, the data from 11 studies on the small intestinal immune cell counts in IBS vs control are summarized in Table 2 . Ten of these studies indicated that small intestinal mast cells are increased in IBS patients.
| DISCUSSION
IBS is a functional GI disorder not associated with overt macroscopic abnormalities in the structure of the gut. Nonetheless, evidence has been accumulating over the years suggesting that altered immune signaling is a potential pathophysiological mechanism of IBS. This includes the identification of altered intestinal or circulating cytokine levels and secretion, and cytokine gene polymorphisms that are associated with IBS. 2, 9, 32 In the current meta-analysis, we showed a significant increase in the number of mast cells in the descending and rectosigmoid colon of IBS patients. 5, [12] [13] [14] [15] 17, 19, 20 In addition, the meta-analysis 
1,35,36
The possible relevance of mast cells in symptom generation in IBS has been the focus of several studies. In a cross-over clinical trial, Daryani et al. showed that the mast cell stabilizer cromolyn sodium decreased abdominal pain in IBS patients without any significant effect on their bowel habits. 37 Based on earlier studies, cromolyn sodium has antidiarrheal effect in patients with IBS-like symptoms, possibly associated with food allergies. 38, 39 In addition, a recently published study has shown that the H1 receptor blocker ebastine reduces visceral hypersensitivity and abdominal pain scores and increases symptom relief in IBS. 40 The therapeutic response to mast cell stabilizers in IBS is also in agreement with other studies which showed an increased histaminergic activity in IBS. Histamine has been shown to be increased in biopsy supernatants, 4, 13 and to activate human colonic submucosal neurons and primary afferents. 4, 5 On the other hand, a study showed that the number of mast cells in the colonic mucosa of patients with IBS was not increased (or even decreased) compared to controls. In this study, an eight-week treatment period with the mast cell stabilizer ketotifen decreased visceral hypersensitivity, reduced abdominal pain and improved the quality of life of the IBS patients. However, ketotifen did not change the number of mucosal mast cells. 7 These data suggest that the therapeutic effects of ketotifen in IBS are largely independent of mast cell number modulation.
In our meta-analysis, increased number of colonic mast cells was observed in both IBS-D and IBS-C patients, challenging the general belief that low-grade immune activation is confined to IBS-D, but providing support to the functional studies showing similar actions of biopsy supernatants in these two subgroups. 4 Our experience with analyses of cytokines also supports the notion that immune activation is not restricted to IBS-D. 2, 9 In addition, one study revealed a significantly higher number of mast cells overall, or in single colonic segments, in patients with slow transit constipation compared to controls, supporting the role of mast cells in constipation and potentially found to have any effect on these nerve populations. 42 Finally, a normality cut-off for the T cell count should be defined to differentiate IBS from lymphocytic colitis. Based on Lazenby and colleagues, lymphocytic colitis is defined as increased IEL, considering a median of 30 lymphocytes/100 epithelial cells. 44, 45 Whether the studies on IBS have sufficiently excluded patients with lymphocytic colitis also needs further evaluation.
As for the segmental differences on lymphocytes in the gut, the 
17,26,27
Finally, regarding the small intestine, 11 studies had reported mast cell and IEL counts in IBS vs healthy controls. Overall, 10 of these 11 studies indicated that small intestinal mast cells are increased in IBS patients. These findings have also been reported in two systematic reviews by Nasser et al 49 and Hughes et al 50 However, only five of these studies measured IELs and these had mixed results. To draw a firmer conclusion regarding the role of small intestinal immune cells in IBS, future additional studies and meta-analyses are necessary.
In summary, despite our meta-analysis showing increased colonic infiltration with mast cells and T cells in IBS patients, data from some isolated studies showed unchanged or decreased mast cell counts in IBS compared to healthy controls. 6, 18, 26, 27 As discussed previously by
Chang et al, 18 the reason for these disparate findings could be due to heterogeneity of the studied subjects, tissue collection methods, different cell count methodologies or small sample size of the stud- T A B L E 2 Small intestinal mast cells and intraepithelial lymphocytes (IELs) in IBS vs controls
